MGX NASDAQ Week ended 24 Jul 2026

Weekly Investor Report

Metagenomi, Inc. Common Stock · Healthcare · Biotechnology

Open interactive chart View report data Download investor PDF
Latest close 1.21 USD
-2.8% latest week
Weekly setup

Weak trend

The weekly trend is not active. Price is -14.8% below the Trend Line and sits at 2.7% of its 52-week range. The latest completed week returned -2.8%, after a -3.6% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 52/100. Near-term considerations: earnings are due in 13d.

Setup score 26 out of 100
Latest Close 1.21 USD 24 Jul 2026
1W Return -2.8% latest completed week
4W Return -3.6% short-term follow-through
12W Return -13.3% quarterly tape
Trend Breadth 19.2% 10 of 52 weeks active
Volume Ratio 1.2x vs 13-week average
What is working
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 43.00% based on similar historical setup states.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -2.8% Latest completed week; four-week move -3.6%. Indicator stack 11/69 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.00% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 52/100 44 relevant articles in the latest sentiment read. Event risk 13d Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -14.8% below the Trend Line and sits at 2.7% of its 52-week range. The latest completed week returned -2.8%, after a -3.6% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 1.2x the 13-week average. Participation is around or above normal and provides reasonable confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
30 Jan 6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0312-week average 0.03

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure4/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.03Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -3.6% over four weeks, -13.3% over 12 weeks, and -50.4% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W-2.8%
4W-3.6%
12W-13.3%
26W-28.7%
52W-50.4%
Active trend streak0 weeks
Active weeks in one year10
Trend breadth19.2%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.31Latest activity-pressure read.
Pressure change173.7%Four-week change in activity pressure.
Leadership-35.80Latest relative-leadership reading.
RS change7.8%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Dec 2025 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength51/100Blend of value, momentum, and quality. Underlying universe rank 50; rank 1 is best.
Value50/100Relative valuation strength. Underlying universe rank 51; rank 1 is best.
Quality48/100Profitability and accounting quality. Underlying universe rank 53; rank 1 is best.
Momentum50/100Medium-term price momentum. Underlying universe rank 51; rank 1 is best.
Growth50/100Revenue and earnings growth. Underlying universe rank 51; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
2.0x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-146.7%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-16.4%
Gross profit retained from each unit of revenue.
Operating margin
-385.3%
Operating profit retained from revenue.
Free-cash-flow margin
-389.2%
Free cash flow generated from revenue.
Return on invested capital
-42.5%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-50.7%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
0/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
0.0%
Net share repurchases relative to market value.
Shareholder yield
0.0%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.2x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment52/100

Weighted news tone is neutral across 44 relevant articles.

10 positive · 28 neutral · 6 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-69.5%Distance below the 52-week high.
13-week volatility3.8%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2612 weeks finished lower.
Best week+7.2%Week of 17 Apr.
Worst week-8.9%Week of 30 Jan.
Latest week-2.8%Week of 24 Jul.

Shape of recent returns

Strong gains3
Modest gains8
Flat weeks3
Modest losses5
Sharp losses7
Recent vol3.8%13-week weekly-return volatility.
Base vol7.5%52-week weekly-return volatility.
Up/down split23/26Count of positive and negative weeks in the 52-week window.
Average skew5.5% / -7.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape25/100

Trend, activity pressure, participation, and risk combine to a 25/100 tape read.

 Indicator analysis16/100

Latest 12-week confirmation: trend 0/12, activity pressure 4/12, relative leadership 0/12.

Activity pressure 0.03; No reversal markers Next-Week ExpectancyNegative 43.00%

Next-week expectancy is negative with a 43.00% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors49/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 50 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment52/100

Weighted news tone is neutral across 44 relevant articles.

Metagenomi Therapeutics, Inc. Revenue Breakdown – NASDAQ:MGX Insiders50/100

No recent insider transaction evidence is stored.

 Earnings13d

Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
24 Jul 20261.21 USD-2.8%1.41 USD3.09 USD0.31-35.801.0MOff
17 Jul 20261.24 USD-2.4%1.43 USD3.11 USD0.27-36.131.0MOff
10 Jul 20261.27 USD0.8%1.45 USD3.12 USD0.07-38.071.2MOff
3 Jul 20261.26 USD0.8%1.46 USD3.14 USD-0.27-38.36862.4KOff
26 Jun 20261.25 USD4.2%1.48 USD3.15 USD-0.42-38.84541.1KOff
19 Jun 20261.20 USD0.0%1.50 USD3.17 USD-0.32-44.26862.5KOff
12 Jun 20261.20 USD-6.3%1.51 USD3.18 USD-0.14-43.20445.5KOff
5 Jun 20261.28 USD-5.9%1.52 USD3.20 USD-0.01-38.44919.9KOff
29 May 20261.36 USD0.7%1.55 USD3.22 USD0.09-38.13822.4KOff
22 May 20261.35 USD3.1%1.59 USD3.23 USD-0.06-37.39974.7KOff
15 May 20261.31 USD-7.1%1.64 USD3.25 USD-0.05-39.021.1MOff
8 May 20261.41 USD1.4%1.70 USD3.26 USD-0.05-35.13735.2KOff
1 May 20261.39 USD-7.3%1.75 USD3.28 USD-0.26-33.01593.1KOff
24 Apr 20261.50 USD1.4%1.79 USD3.30 USD-0.35-27.151.0MOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.